This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mangues, R. Articles by Pellicer, A. Search for Related Content PubMed PubMed Citation Articles by Mangues, R. Articles by Pellicer, A.

An Overexpressed N-ras Proto-oncogene Cooperates with N-Methylnitrosourea in Mouse Mammary Carcinogenesis¹

Department of Pathology and Kaplan Cancer Center, New York University Medical Center, New York, New York 10016

The induction of tumors with chemicals and the production of transgenic animals are two experimental approaches to study oncogene involvement in carcinogenesis. The combination of both strategies offers an excellent model system to study tumor development. This study analyzes the potential cooperation of N-methylnitrosourea (MNU) treatment and N-ras proto-oncogene overexpression in tumorigenesis in transgenic mice. The overexpression of the N-ras proto-oncogene in these animals is associated with development of mammary tumors and lymphomas. After MNU treatment we analyzed tumor incidence and latency, levels of transgene expression, and pattern of ras mutations in codons 12, 13, and 61 of H-, K-, and N-ras genes in both tumor types. Transgenic mice treated with MNU had significantly (P < 0.001) shorter latency of appearance of mammary tumors [8.6 ± 3.0 (SD) months] than phosphate-buffered saline-treated transgenics (12.8 ± 2.3 months). All mammary tumors overexpressed the N-ras transgene and lacked ras mutations. Moreover, MNU-treated transgenics had an incidence and latency of lymphomas similar to that of MNU-treated nontransgenic mice. No significant differences in incidence of point mutations (K-ras codon 12 or 13 and N-ras codon 61) in lymphomas were seen between these two groups. All lymphomas overexpressed the N-ras transgene, except for those carrying a K-ras point mutation. Overexpression of the N-ras proto-oncogene cooperates with non-ras genes mutated by MNU in mouse mammary carcinogenesis. Conversely, N-ras proto-oncogene overexpression does not show cooperation with MNU in lymphomagenesis in our system. This study suggests that proto-oncogene overexpression may be a mechanism of activation of the ras pathway, alternative to point mutation. Similarly to actions for ras genes activated by point mutation, overexpression of the N-ras proto-oncogene predisposes to tumorigenesis and cooperates with a carcinogen in tumorigenesis. The possibility that ras overexpression plays a role in human breast tumorigenesis requires active investigation.

¹ R. M. acknowledges support from the Spanish Ministry of Education and Science (FPU-91 40859166). This study was conducted with support from Grants CA36327 and CA50434 to A. P.

² To whom requests for reprints should be addressed.

Received 6/23/94. Accepted 10/14/94.

This article has been cited by other articles:

				S. R. Nesfield, C. J. Clarke, D. J. Hoivik, R. T. Miller, J. S. Allen, K. Selinger, and M. J. Santostefano Evaluation of the Carcinogenic Potential of Clofibrate in the rasH2 Mouse International Journal of Toxicology, September 1, 2005; 24(5): 301 - 311. [Abstract] [Full Text] [PDF]

				R. Diaz, L. Lopez-Barcons, D. Ahn, A. Garcia-Espana, A. Yoon, J. Matthews, R. Mangues, R. Perez-Soler, and A. Pellicer Complex effects of Ras proto-oncogenes in tumorigenesis Carcinogenesis, April 1, 2004; 25(4): 535 - 539. [Abstract] [Full Text] [PDF]

				R. Diaz, D. Ahn, L. Lopez-Barcons, M. Malumbres, I. Perez de Castro, J. Lue, N. Ferrer-Miralles, R. Mangues, J. Tsong, R. Garcia, et al. The N-ras Proto-oncogene Can Suppress the Malignant Phenotype in the Presence or Absence of Its Oncogene Cancer Res., August 1, 2002; 62(15): 4514 - 4518. [Abstract] [Full Text] [PDF]

				R. Sotillo, J. F. Garcia, S. Ortega, J. Martin, P. Dubus, M. Barbacid, and M. Malumbres Invasive melanoma in Cdk4-targeted mice PNAS, October 16, 2001; (2001) 241338598. [Abstract] [Full Text] [PDF]

				Z.-M. Shao, J. Wu, Z.-Z. Shen, and M. Nguyen p53 Mutation in Plasma DNA and Its Prognostic Value in Breast Cancer Patients Clin. Cancer Res., August 1, 2001; 7(8): 2222 - 2227. [Abstract] [Full Text] [PDF]

				J I Goodman Response to "Epigenetic Mechanisms of Carcinogenesis" by Kamendunlis JE, Kamendulis LM and Xu Y Human and Experimental Toxicology, October 1, 2000; 19(10): 563 - 565. [PDF]

				C.-K. Lee, E. Smith, R. Gimeno, R. Gertner, and D. E. Levy STAT1 Affects Lymphocyte Survival and Proliferation Partially Independent of Its Role Downstream of IFN-{gamma} J. Immunol., February 1, 2000; 164(3): 1286 - 1292. [Abstract] [Full Text] [PDF]

				X. Qin, H. Zhou, L. Liu, and S. L. Gerson Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis Carcinogenesis, September 1, 1999; 20(9): 1667 - 1673. [Abstract] [Full Text] [PDF]

				I. P. de Castro, M. Malumbres, J. Santos, A. Pellicer, and J. Fernandez-Piqueras Cooperative alterations of Rb pathway regulators in mouse primary T cell lymphomas Carcinogenesis, September 1, 1999; 20(9): 1675 - 1682. [Abstract] [Full Text] [PDF]

				J. M. Silva, G. Dominguez, J. M. Garcia, R. Gonzalez, M. J. Villanueva, F. Navarro, M. Provencio, S. San Martin, P. Espana, and F. Bonilla Presence of Tumor DNA in Plasma of Breast Cancer Patients: Clinicopathological Correlations Cancer Res., July 1, 1999; 59(13): 3251 - 3256. [Abstract] [Full Text] [PDF]

				C. M. Bral and K. S. Ramos Identification of Benzo[a]pyrene-Inducible Cis-Acting Elements Within c-Ha-ras Transcriptional Regulatory Sequences Mol. Pharmacol., December 1, 1997; 52(6): 974 - 982. [Abstract] [Full Text]

				R. Sotillo, J. F. Garcia, S. Ortega, J. Martin, P. Dubus, M. Barbacid, and M. Malumbres Invasive melanoma in Cdk4-targeted mice PNAS, November 6, 2001; 98(23): 13312 - 13317. [Abstract] [Full Text] [PDF]